Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1

被引:14
作者
Du, Yifei [1 ,2 ]
Zhang, Shuangyue [1 ,2 ]
Wang, Zilu [2 ]
Zhou, Weina [2 ]
Luan, Mingliang [1 ,2 ]
Yang, Xiaohan [1 ,2 ]
Chen, Ning [1 ,2 ]
机构
[1] Nanjing Med Univ, Sch Stomatol, Dept Oral & Maxillofacial Surg, Nanjing 210029, Peoples R China
[2] Nanjing Med Univ, Inst Dent Res, Nanjing 210029, Peoples R China
关键词
COX-2; E2F-1; oral cancer; apoptosis; immuohistochemistry;
D O I
10.3892/or_00000048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of cyclooxygenase-2 (COX-2) plays an important role in development and progression of different human cancers, but the underlying molecular mechanisms remain to be defined. Tissue specimens of normal oral epithelia (n=9), dysplasia (n=38), and oral squamous cell carcinoma (SCC, n=54) were immunohistochemically analyzed for COX-2 and E2F-1 expression. A human oral SCC cell line, Tca8113, was used to assess NS398 antitumor activity. PGE, levels were measured by using radioimmunoassay, and COX-2, pRb, and E2F-1 proteins were determined by Western blot assay. We found expression of COX-2 and E2F-1 proteins was significantly increased in both oral dysplasia and SCC compared to the normal epithelium. Increased COX-2 expression was associated with E2F-1 expression in both oral dysplasia and SCC. NS398 treatment reduced viability of Tca8113 cells in a dose- and time-dependent manner. NS398 suppressed PGE, levels, a product of COX-2 enzyme, in the tumor cells. The reduced cell viability is due to induction of apoptosis by NS398, which activates caspase-3, but does not inhibit bcl-2. NS398 also induced tumor cell arrest at G1 phase of the cell cycle and inhibited expression of COX-2, pRb and E2F-1 proteins. This study provides evidence that E2F-1 and COX-2 are overexpressed in oral cancer, and further supports suppression of COX-2 in control of oral cancer.
引用
收藏
页码:605 / 611
页数:7
相关论文
共 38 条
[1]   Celecoxib toxicity is cell cycle phase specific [J].
Bock, Jonathan M. ;
Menon, Sarita G. ;
Sinclair, Lori L. ;
Bedford, Nichole S. ;
Goswami, Prahhat C. ;
Domann, Frederick E. ;
Trask, Douglas K. .
CANCER RESEARCH, 2007, 67 (08) :3801-3808
[2]   Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines [J].
Buecher, B ;
Broquet, A ;
Bouancheau, D ;
Heymann, MF ;
Jarry, A ;
Denis, MG ;
Bonnet, C ;
Galmiche, JP ;
Blottière, HM .
DIGESTIVE AND LIVER DISEASE, 2003, 35 (08) :557-565
[3]   Emerging roles for E2F: Beyond the G1/S transition and DNA replication [J].
Cam, H ;
Dynlacht, BD .
CANCER CELL, 2003, 3 (04) :311-316
[4]   Histologically normal human mammary epithelia with silenced p16INK4a overexpress COX-2, promoting a premalignant program [J].
Crawford, YG ;
Gauthier, ML ;
Joubel, A ;
Mantei, K ;
Kozakiewicz, K ;
Afshari, CA ;
Tlsty, TD .
CANCER CELL, 2004, 5 (03) :263-273
[5]   Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells [J].
Davis, JN ;
McCabe, MT ;
Hayward, SW ;
Park, JM ;
Day, ML .
CANCER RESEARCH, 2005, 65 (09) :3633-3642
[6]   Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference [J].
Denkert, C ;
Fürstenberg, A ;
Daniel, PT ;
Koch, I ;
Köbel, M ;
Weichert, W ;
Siegert, A ;
Hauptmann, S .
ONCOGENE, 2003, 22 (54) :8653-8661
[7]   Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression [J].
Ebihara, Y ;
Miyamoto, M ;
Shichinohe, T ;
Kawarada, Y ;
Cho, Y ;
Fukunaga, A ;
Murakami, S ;
Uehara, H ;
Kaneko, H ;
Hashimoto, H ;
Murakami, Y ;
Itoh, T ;
Okushiba, S ;
Kondo, S ;
Katoh, H .
DISEASES OF THE ESOPHAGUS, 2004, 17 (02) :150-154
[8]  
Elder DJE, 1997, CLIN CANCER RES, V3, P1679
[9]   COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib [J].
Grösch, S ;
Tegeder, I ;
Niederberger, E ;
Bräutigam, L ;
Geisslinger, G .
FASEB JOURNAL, 2001, 15 (12) :2742-+
[10]  
HELENA A, 2003, CLIN CANCER RES, V5, P1885